Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies

References

• Manh TP, Alexandre Y, Baranek T, et al. Plasmacytoid, conventional, and monocyte-derived dendritic cells undergo a profound and convergent genetic reprogramming during their maturation. Eur J Immunol. 2013 Jul;43(7):1706–1715. doi:10.1002/eji.201243106.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013 Jul 25;39(1):38–48.
   PubMed Web of Science ®Google Scholar
• Steinbrink K, Graulich E, Kubsch S, et al. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood. 2002 Apr 1;99(7):2468–2476.
   PubMed Web of Science ®Google Scholar
• Legge KL, Gregg RK, Maldonado-Lopez R, et al. On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity. J Exp Med. 2002 Jul 15;196(2):217–227.
   PubMed Web of Science ®Google Scholar
• Van Brussel I, Lee WP, Rombouts M, et al. Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality? Autoimmun Rev. 2014 Feb;13(2):138–150. doi:10.1016/j.autrev.2013.09.008.
   PubMed Web of Science ®Google Scholar
• Xing Y, Hogquist KA. T-cell tolerance: central and peripheral. Cold Spring Harb Perspect Biol. 2012 Jun;4(6). doi:10.1101/cshperspect.a006957.
   PubMed Web of Science ®Google Scholar
• `Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012 Apr;12(4):253–268. doi:10.1038/nri3175.
   PubMed Web of Science ®Google Scholar
• Idris SZ, Hassan N, Lee LJ, et al. Increased regulatory T cells in acute lymphoblastic leukaemia patients. Hematology. 2016 Feb 23. doi:10.1080/10245332.2015.1101965.
   PubMed Web of Science ®Google Scholar
• Wang ZT, Zhang LL, Wang HP, et al. Tumor-induced CD14(+)HLA-DR-/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients. Cancer Immunol Immun. 2015 Mar;64(3):389–399. doi:10.1007/s00262-014-1646-4.
   PubMed Web of Science ®Google Scholar
• Jitschin R, Braun M, Buttner M, et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014 Jul 31;124(5):750–760.
   PubMed Web of Science ®Google Scholar
• Frassanito MA, Ruggieri S, Desantis V, et al. Myeloma cells act as tolerogenic antigen-presenting cells and induce regulatory T cells in vitro. Eur J Haematol. 2015 Jul;95(1):65–74. doi:10.1111/ejh.12481.
   PubMed Web of Science ®Google Scholar
• Onodera T, Jang MH, Guo Z, et al. Constitutive expression of IDO by dendritic cells of mesenteric lymph nodes: functional involvement of the CTLA-4/B7 and CCL22/CCR4 interactions. J Immunol. 2009 Nov 1;183(9):5608–5614.
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol. 2011 Feb;11(2):119–130. doi:10.1038/nri2916.
   PubMed Web of Science ®Google Scholar
• Koch F, Stanzl U, Jennewein P, et al. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med. 1996 Aug 1;184(2):741–746.
   PubMed Web of Science ®Google Scholar
• De Smedt T, Van Mechelen M, De Becker G, et al. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol. 1997 May;27(5):1229–1235. doi:10.1002/eji.1830270526.
   PubMed Web of Science ®Google Scholar
• Adorini L, Giarratana N, Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol. 2004 Apr;16(2):127–134. doi:10.1016/j.smim.2003.12.008.
   PubMed Web of Science ®Google Scholar
• Li HB, Shi BY. Tolerogenic dendritic cells and their applications in transplantation. Cell Mol Immunol. 2015 Jan;12(1):24–30. doi:10.1038/cmi.2014.52.
   PubMed Web of Science ®Google Scholar
• Torres-Aguilar H, Aguilar-Ruiz SR, Gonzalez-Perez G, et al. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4(+) T cells. J Immunol. 2010 Feb 15;184(4):1765–1775.
   PubMed Web of Science ®Google Scholar
• Lan YY, Wang Z, Raimondi G, et al. “Alternatively activated” dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. J Immunol. 2006 Nov 1;177(9):5868–5877. doi:10.4049/jimmunol.177.9.5868.
   PubMed Web of Science ®Google Scholar
• Panther E, Corinti S, Idzko M, et al. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood. 2003 May 15;101(10):3985–3990.
   PubMed Web of Science ®Google Scholar
• Yang M, Ma C, Liu S, et al. HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia. Immunol Cell Biol. 2010 Feb;88(2):165–171. doi:10.1038/icb.2009.77.
   PubMed Web of Science ®Google Scholar
• Novitskiy SV, Ryzhov S, Zaynagetdinov R, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood. 2008 Sep 1;112(5):1822–1831.
   PubMed Web of Science ®Google Scholar
• Nasi A, Fekete T, Krishnamurthy A, et al. Dendritic cell reprogramming by endogenously produced lactic acid. J Immunol. 2013 Sep 15;191(6):3090–3099.
   PubMed Web of Science ®Google Scholar
• Hardwick N, Chan L, Ingram W, et al. Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80. Cancer Immunol Immunother. 2010 Mar;59(3):379–388. doi:10.1007/s00262-009-0756-x.
   PubMed Web of Science ®Google Scholar
• Narita M, Watanabe N, Yamahira A, et al. A leukemic plasmacytoid dendritic cell line, PMDC05, with the ability to secrete IFN-alpha by stimulation via Toll-like receptors and present antigens to naive T cells. Leuk Res. 2009 Sep;33(9):1224–1232. doi:10.1016/j.leukres.2009.03.047.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012 Apr;12(4):265–277. doi:10.1038/nrc3258.
   PubMed Web of Science ®Google Scholar
• Chiang CL, Coukos G, Kandalaft LE. Whole tumor antigen vaccines: where are we? Vaccines (Basel). 2015;3(2):344–372. doi:10.3390/vaccines3020344.
   PubMed Web of Science ®Google Scholar
• Gonzalez FE, Gleisner A, Falcon-Beas F, et al. Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum Vaccin Immunother. 2014;10(11):3261–3269. doi:10.4161/21645515.2014.982996.
   PubMed Web of Science ®Google Scholar
• Mantia-Smaldone GM, Chu CS. A review of dendritic cell therapy for cancer: progress and challenges. BioDrugs. 2013 Oct;27(5):453–468. doi:10.1007/s40259-013-0030-9.
   PubMed Web of Science ®Google Scholar
• Suresh K, Fraser G, Scheid E, et al. Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate. Leuk Lymphoma. 2006 Feb;47(2):297–306. doi:10.1080/10428190500301231.
   PubMed Web of Science ®Google Scholar
• Lim JH, Park CJ, Kim MJ, et al. Generation of lymphocytes potentiated against leukemic lymphoblasts by stimulation using leukemic cell lysate-pulsed dendritic cells in patients with acute lymphoblastic leukemia and measurement of in vitro anti-leukemic cytotoxicity. Hematology. 2012 Jan;17(1):15–22. doi:10.1179/102453312X13221316477453.
   PubMed Web of Science ®Google Scholar
• Alaniz L, Rizzo MM, Mazzolini G. Pulsing dendritic cells with whole tumor cell lysates. Methods Mol Biol. 2014;1139:27–31. doi:10.1007/978-1-4939-0345-0_3.
   PubMedGoogle Scholar
• Hatfield P, Merrick AE, West E, et al. Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J Immunother. 2008 Sep;31(7):620–632. doi:10.1097/CJI.0b013e31818213df.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Paczesny S, Blanco P, et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci. 2003;987:180–187.
   PubMed Web of Science ®Google Scholar
• Westers TM, Van Den Ancker W, Bontkes HJ, et al. Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells. Immunotherapy. 2011 Apr;3(4):569–576. doi:10.2217/imt.11.3.
   PubMed Web of Science ®Google Scholar
• Duman BB, Sahin B, Ergin M, et al. Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature. Med Oncol. 2012 Jun;29(2):1223–1226. doi:10.1007/s12032-011-9955-3.
   PubMed Web of Science ®Google Scholar
• Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015 Jul 30;126(5):573–581.
   PubMed Web of Science ®Google Scholar
• Hus I, Schmitt M, Tabarkiewicz J, et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia. 2008 May;22(5):1007–1017. doi:10.1038/leu.2008.29.
   PubMed Web of Science ®Google Scholar
• Yamahira A, Narita M, Nakamura T, et al. Generation of antigen-specific cytotoxic T lymphocytes using a leukemic plasmacytoid dendritic cell line as antigen presenting cells. Leuk Res. 2011 Jun;35(6):793–799. doi:10.1016/j.leukres.2010.12.003.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Casalegno-Garduno R, Xu X, et al. Peptide vaccines for patients with acute myeloid leukemia. Expert Rev Vaccines. 2009 Oct;8(10):1415–1425. doi:10.1586/erv.09.90.
   PubMed Web of Science ®Google Scholar
• Bijker MS, Melief CJ, Offringa R, et al. Design and development of synthetic peptide vaccines: past, present and future. Expert Rev Vaccines. 2007 Aug;6(4):591–603. doi:10.1586/14760584.6.4.591.
   PubMed Web of Science ®Google Scholar
• Maeda T, Hosen N, Fukushima K, et al. Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine. Blood Cancer J. 2013;3:e130. doi:10.1038/bcj.2013.29.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, Jimenez AM, Minagawa K, et al. Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front Immunol. 2015;6:36. doi:10.3389/fimmu.2015.00036.
   PubMed Web of Science ®Google Scholar
• Casalegno-Garduno R, Schmitt A, Schmitt M. Clinical peptide vaccination trials for leukemia patients. Expert Rev Vaccines. 2011 Jun;10(6):785–799. doi:10.1586/erv.11.56.
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Buque A, et al. Trial watch: peptide-based anticancer vaccines. Oncoimmunology. 2015 Apr;4(4):e974411. doi:10.1080/2162402X.2015.1008371.
   Google Scholar
• Pyzer AR, Avigan DE, Rosenblatt J. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies. Hum Vaccin Immunother. 2014;10(11):3125–3131. doi:10.4161/21645515.2014.982993.
   PubMed Web of Science ®Google Scholar
• Hofmann S, Mead A, Malinovskis A, et al. Analogue peptides for the immunotherapy of human acute myeloid leukemia. Cancer Immunol Immunother. 2015 Nov;64(11):1357–1367. doi:10.1007/s00262-015-1762-9.
   PubMed Web of Science ®Google Scholar
• Romano A, Conticello C, Cavalli M, et al. Immunological dysregulation in multiple myeloma microenvironment. Biomed Res Int. 2014;2014:198539. doi:10.1155/2014/198539.
   PubMed Web of Science ®Google Scholar
• Niemann CU, Herman SE, Maric I, et al. Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib - findings from an investigator initiated phase 2 study. Clin Cancer Res. 2016 Apr;22(7):1572–1582. doi:10.1158/1078-0432.CCR-15-1965.
   Web of Science ®Google Scholar
• Pinho MP, Sundarasetty BS, Bergami-Santos PC, et al. Dendritic-tumor cell hybrids induce tumor-specific immune responses more effectively than the simple mixture of dendritic and tumor cells. Cytotherapy. 2016 Apr;18(4):570–580. doi:10.1016/j.jcyt.2016.01.005.
   PubMed Web of Science ®Google Scholar
• Gilboa E. The makings of a tumor rejection antigen. Immunity. 1999 Sep;11(3):263–270.
   PubMed Web of Science ®Google Scholar
• Hus I, Rolinski J, Tabarkiewicz J, et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia. 2005 Sep;19(9):1621–1627. doi:10.1038/sj.leu.2403860.
   PubMed Web of Science ®Google Scholar
• Li L, Giannopoulos K, Reinhardt P, et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int J Oncol. 2006 Apr;28(4):855–861.
   PubMed Web of Science ®Google Scholar
• Berneman N, Van De Velde A, Anguille S, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Haematol Hematol J. 2010;95:461–61.
   Web of Science ®Google Scholar
• Westermann J, Kopp J, Van Lessen A, et al. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl plus chronic myeloid leukaemia. Brit J Haematol. 2007 May;137(4):297–306. doi:10.1111/j.1365-2141.2007.06547.x.
   PubMed Web of Science ®Google Scholar
• Schnorfeil F, Lichtenegger F, Rothe M, et al. Dendritic cell vaccination in postremission therapy of AML: results of a clinical phase i trial and of preclinical studies testing combinatorial approaches. Haematologica. 2015;100:287–87.
   Web of Science ®Google Scholar
• Litzow MR, Dietz AB, Bulur PA, et al. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. Cytotherapy. 2006;8(3):290–298. doi:10.1080/14653240600735743.
   PubMed Web of Science ®Google Scholar
• Roddie H, Klammer M, Thomas C, et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol. 2006 Apr;133(2):152–157. doi:10.1111/j.1365-2141.2006.05997.x.
   PubMed Web of Science ®Google Scholar
• Ossenkoppele GJ, Stam AG, Tm W, et al. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia. 2003 Jul;17(7):1424–1426. doi:10.1038/sj.leu.2402979.
   PubMed Web of Science ®Google Scholar
• Fujii S, Shimizu K, Fujimoto K, et al. Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn J Cancer Res. 1999 Oct;90(10):1117–1129.
   PubMedGoogle Scholar
• Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia. 2012 Oct;26(10):2186–2196. doi:10.1038/leu.2012.145.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Li L, Giannopoulos K, et al. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. Exp Hematol. 2006 Dec;34(12):1709–1719. doi:10.1016/j.exphem.2006.07.009.
   PubMed Web of Science ®Google Scholar
• Greiner J, Schmitt M, Li L, et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood. 2006 Dec 15;108(13):4109–4117. doi:10.1182/blood-2006-01-023127.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Schmitt M. Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2006 Oct;47(10):2028–2036. doi:10.1080/10428190600709721.
   PubMed Web of Science ®Google Scholar
• Kowalewski DJ, Schuster H, Backert L, et al. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166–75.
   PubMed Web of Science ®Google Scholar
• Berlin C, Kowalewski DJ, Schuster H, et al. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia. 2015 Mar;29(3):647–659. doi:10.1038/leu.2014.233.
   PubMed Web of Science ®Google Scholar
• Weinzierl AO, Lemmel C, Schoor O, et al. Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics. 2007 Jan;6(1):102–113. doi:10.1074/mcp.M600310-MCP200.
   PubMed Web of Science ®Google Scholar
• Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012 Aug;18(8):1254–1261. doi:10.1038/nm.2883.
   PubMed Web of Science ®Google Scholar
• Garg AD, Vandenberk L, Koks C, et al. Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. Sci Transl Med. 2016 Mar 2;8(328):328ra27. doi:10.1126/scitranslmed.aaf0746.
   PubMed Web of Science ®Google Scholar
• Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev. 2004 Jun;199:251–263. doi:10.1111/j.0105-2896.2004.00139.x.
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Van De Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13824–13829. doi:10.1073/pnas.1008051107.
   PubMed Web of Science ®Google Scholar
• Subklewe M, Geiger C, Lichtenegger FS, et al. New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunol Immunother. 2014 Oct;63(10):1093–1103. doi:10.1007/s00262-014-1600-5.
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011 Aug 25;365(8):725–733.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013 Apr 18;368(16):1509–1518.
   PubMed Web of Science ®Google Scholar
• Ramos CA, Heslop HE, Brenner MK. CAR-T Cell Therapy for Lymphoma. Annu Rev Med. 2016 Jan 14;67:165–183. doi:10.1146/annurev-med-051914-021702.
   PubMed Web of Science ®Google Scholar
• Sundarasetty BS, Singh VK, Salguero G, et al. Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia. Hum Gene Ther. 2013 Feb;24(2):220–237. doi:10.1089/hum.2012.128.
   PubMed Web of Science ®Google Scholar
• Sundarasetty BS, Kloess S, Oberschmidt O, et al. Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantation. J Transl Med. 2015;13:240. doi:10.1186/s12967-015-0541-x.
   PubMed Web of Science ®Google Scholar
• Sundarasetty BS, Chan L, Darling D, et al. Lentivirus-induced ‘Smart’ dendritic cells: pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma. Gene Ther. 2015 Sep;22(9):707–720. doi:10.1038/gt.2015.43.
   PubMed Web of Science ®Google Scholar
• Rickmann M, Macke L, Sundarasetty BS, et al. Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia. Ann Hematol. 2013 Aug;92(8):1079–1090. doi:10.1007/s00277-013-1744-y.
   PubMed Web of Science ®Google Scholar
• Rickmann M, Krauter J, Stamer K, et al. Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. Ann Hematol. 2011 Sep;90(9):1047–1058. doi:10.1007/s00277-011-1231-2.
   PubMed Web of Science ®Google Scholar
• Stripecke R, Cardoso AA, Pepper KA, et al. Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage-colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood. 2000 Aug 15;96(4):1317–1326.
   PubMed Web of Science ®Google Scholar
• Ackerman AL, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol. 2004 Jul;5(7):678–684. doi:10.1038/ni1082.
   PubMed Web of Science ®Google Scholar
• Tacken PJ, Joosten B, Reddy A, et al. No advantage of cell-penetrating peptides over receptor-specific antibodies in targeting antigen to human dendritic cells for cross-presentation. J Immunol. 2008 Jun 1;180(11):7687–7696.
   PubMed Web of Science ®Google Scholar
• Kretz-Rommel A, Qin F, Dakappagari N, et al. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J Immunother. 2007 Oct;30(7):715–726. doi:10.1097/CJI.0b013e318135472c.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015 Jul 2;373(1):23–34. doi:10.1056/NEJMoa1504030.
   PubMed Web of Science ®Google Scholar